Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02157103 · ClinicalTrials.gov registry record · Phase 2

A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma

A Phase 2 study of Glioblastoma, sponsored by Emory University.

Completed
Registry status
Phase 2
Development phase
3
Enrollment target
2
Study locations

NCT02157103 is a Phase 2 study of Glioblastoma that has completed, run by Emory University. The registered enrollment target is 3 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02157103, a Phase 2 study of Glioblastoma, has completed, sponsored by Emory University.

COMPLETED
Registry status
Phase 2
Development phase
3 participants
Enrollment target
2
Study locations

Study Summary

STUDY BACKGROUND: This research will involve patients with glioblastoma. The drug bevacizumab (Avastin) is FDA approved for the treatment of glioblastoma that gets worse after standard therapy. For glioblastoma, bevacizumab is given by vein every 14 days. The purpose of this study is to see if bevacizumab works as well when it is given as a daily subcutaneous shot as it does when given intravenously. A subcutaneous shot is like an insulin shot or a heparin shot. The dose of bevacizumab given on this study is in total slightly lower than the FDA approved dose for glioblastoma. STUDY DESCRIPTION: About 10 people will take part in the study. Participants or caregivers will be educated on injection and given prefilled syringes to take home. Participants or caregivers will administer bevacizumab subcutaneously each day. The bevacizumab will be stored in the refrigerator. Follow up visits will be weekly for the first 3 weeks, then every 3 weeks. After 18 weeks, the follow up interval can be increased to every 6 weeks at the treating physician's discretion. Participants can keep taking the bevacizumab until: * Tests show that they are not benefiting from it, * The participant has a bad side effect related to study treatment, * The participant can no longer comply with study requirements, or * The participant or doctor feels it is no longer in the participant's best interest.

Conditions Studied

Glioblastoma

Interventions

  • DRUG Bevacizumab 25 mg in 1 ml subcutaneously daily

Study Locations (2)

Georgia

  • Emory University Hospital Midtown - Atlanta
  • Emory University Winship Cancer Institutute - Atlanta

Trial Details

FieldValue
Enrollment Target 3 participants
Start Date 2014-01
Est. Completion 2018-01
Phase Phase 2

Sponsor

Emory University

1,208 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02157103

The ClinicalTrials.gov registry entry for NCT02157103 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (97% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which Bevacizumab 25 mg in 1 ml subcutaneously daily is the first listed.

NCT02157103 reports 2 study locations spanning 1 distinct geographic area - top geographies include Georgia.

Frequently Asked Questions

What is clinical trial NCT02157103 about?

NCT02157103 is a clinical study titled "A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma". STUDY BACKGROUND: This research will involve patients with glioblastoma. The drug bevacizumab (Avastin) is FDA approved for the treatment of glioblastoma that gets worse after standard therapy. For glioblastoma, bevacizumab is given by vein every 14 days. The purpose of this study is to see if beva...

What is the current status of trial NCT02157103?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2014-01. Estimated completion is 2018-01.

What conditions does trial NCT02157103 study?

This clinical trial studies the following conditions: Glioblastoma.

What interventions are being tested in trial NCT02157103?

The interventions under investigation include: Bevacizumab 25 mg in 1 ml subcutaneously daily (DRUG).

Who is sponsoring clinical trial NCT02157103?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02157103 being conducted?

This trial has 2 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Glioblastoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Glioblastoma

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.